{"id":"NCT00055497","sponsor":"Abbott","briefTitle":"Remission in Subjects With Crohn's Disease, 1 Year Phase","officialTitle":"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-08","primaryCompletion":"2005-01","completion":"2008-12","firstPosted":"2003-03-05","resultsPosted":"2010-05-18","lastUpdate":"2011-04-11"},"enrollment":276,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Double-blind (DB) adalimumab placebo","otherNames":["Humira速"]},{"type":"BIOLOGICAL","name":"DB adalimumab 40 mg eow","otherNames":["Humira速"]},{"type":"BIOLOGICAL","name":"DB adalimumab 40 mg ew","otherNames":["Humira速"]},{"type":"BIOLOGICAL","name":"OL adalimumab 40 mg","otherNames":["Humira速"]}],"arms":[{"label":"Double-blind (DB) adalimumab placebo","type":"PLACEBO_COMPARATOR"},{"label":"Double-blind adalimumab 40 mg every other week (eow)","type":"EXPERIMENTAL"},{"label":"Double-blind adalimumab 40 mg every week (ew)","type":"EXPERIMENTAL"},{"label":"Open-label adalimumab 40 mg","type":"EXPERIMENTAL"}],"summary":"The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of adalimumab when administered to participants with Crohn's disease up to 56 weeks.","primaryOutcome":{"measure":"Number of Randomized Participants Achieving Clinical Remission at Week 56 - Non-Responder Imputation (NRI)","timeFrame":"Week 56","effectByArm":[{"arm":"Placebo","deltaMin":6,"sd":null},{"arm":"DB Adalimumab 40 mg Every Other Week (Eow)","deltaMin":9,"sd":null},{"arm":"DB Adalimumab 40 mg Every Week (ew)","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"0.142"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["29380251","22344964"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Nasopharyngitis","Crohn's disease aggravated","Headache","Arthralgia","Nausea"]}}